GlassScriptPhysician profile
Umair Majeed
NPI 1972933125
$4,743.56
in general payments reported to CMS, 2019-2025
25 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $302 · 2021: $100 · 2022: $17.71 · 2023: $1,794 · 2024: $2,146 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,530 · Food and Beverage: $474 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,530.00 |
| Food and Beverage | $474.34 |
| Education | $214.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,713.62 | 2023-2025 | Imfinzi, Enhertu |
| Ipsen Biopharmaceuticals, INC | $366.20 | 2024-2025 | Onivyde |
| Eisai INC. | $132.49 | 2020-2023 | |
| Amgen INC. | $102.71 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $46.54 | 2020-2021 | |
| Genentech USA, INC. | $43.12 | 2019 | |
| Abbvie INC. | $41.61 | 2020 | |
| Kyowa Kirin, INC. | $40.97 | 2020-2021 | |
| Seagen INC. | $33.58 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Welireg |
| Eusa Pharma (US) LLC | $24.82 | 2020 | |
| Puma Biotechnology, INC. | $23.26 | 2020 | |
| Astellas Pharma Global Development | $22.87 | 2020 | |
| Gilead Sciences, INC. | $21.15 | 2025 | |
| Janssen Scientific Affairs, LLC | $20.15 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18.39 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $17.45 | 2019 | |
| Omeros Corporation | $17.02 | 2021 | |
| Kite Pharma, INC. | $16.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.11 | 2023 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umair Majeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.